Amy Keller Named to Crain’s Chicago Business’ “40 Under 40”

Nov 07, 2022

2022 list highlights leaders from the Chicago metropolitan area in a variety of industries

DiCello Levitt Partner and Privacy, Technology, and Cybersecurity Practice Chair Amy Keller has been named to Crain’s Chicago Business’ “40 Under 40” list. The annual list profiles leaders from the Chicago metropolitan area who have made an impact in their respective industries and the greater Chicagoland community.

Amy’s meteoric rise to prominence began when she founded DiCello Levitt’s Privacy, Technology, and Cybersecurity practice group in 2018—after becoming the youngest woman ever selected to lead a nationwide, multidistrict litigation.  At 34, a federal judge entrusted Amy to secure a $1.5 billion settlement against industry giant Equifax.  Amy has now been appointed to lead more multidistrict litigations than any other woman in the United States in the past five years, taking on industry giants like Marriott, Blackbaud, T-Mobile, Facebook, and Coca-Cola.  Her practice group has since been selected Practice Group of the Year by legal publications The National Law Journal (2020), and Law360 (2020 and 2021).

Recognized by Crain’s as having an “eclectic” life, Amy’s talents have led her to pursue a number of interests and passion projects—from working to establish landmark districts to preserve Chicago’s architectural heritage to serving on a number of boards and foundations to safeguard consumer, worker, and environmental protections.  A champion of ensuing that colleagues from underrepresented communities have access to the opportunities afforded to her, Amy frequently uses her platform to speak about the value of diversity in the workplace and courtroom.  Reflecting on her own successes, Amy notes, “I like putting together teams and lifting up women. It’s important to me that I don’t slam the door behind me.”

Read more about Amy in Crain’s Chicago Business “40 Under 40” Class of 2022 (Note: This publication uses a paywall and requires subscription.)  

Comments are closed.